C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients

AstraZeneca3,392 enrolled

Overview

The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy. This study was designed to investigate the dynamic of the lipid parameters and therapy tolerability during 8-10 weeks treatment with CRESTOR

Study Type

OBSERVATIONAL

Enrollment

3,392

Conditions

Hypercholesteremia

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with hypercholesteremia who was never treated with statins before * Patient with hypercholesteremia who was treated with a statin (other then rosuvastatin) but because of its adverse effects/insufficient action was switched to therapy with CRESTOR Exclusion Criteria: * None

Outcomes

Primary Outcomes

LDL-Cholesterin, HDL-Cholesterin, Triglycerides, Total Cholesterin

Time frame: 3 visits within 10 weeks

Secondary Outcomes

Tolerability of CRESTOR-therapy

Time frame: 3 visits within 10 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.